Skip to main content
GUANGDONG BIOLIGHT MEDITECH CO.,LTD. logo

GUANGDONG BIOLIGHT MEDITECH CO.,LTD. — Investor Relations & Filings

Ticker · 300246 ISIN · CNE1000015Q4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,045 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300246

About GUANGDONG BIOLIGHT MEDITECH CO.,LTD.

https://www.blt.com.cn

Guangdong Biolight Meditech Co., Ltd. specializes in the research, development, and manufacturing of medical electronic equipment and healthcare solutions. The company’s core product portfolio includes advanced patient monitoring systems, such as multi-parameter monitors, electrocardiographs, and pulse oximeters. It maintains a significant presence in the renal care sector, providing integrated hemodialysis solutions that encompass dialysis machines, dialyzers, and specialized consumables. Additionally, the company develops home healthcare products and digital health management platforms designed to improve clinical workflows and patient outcomes. By integrating hardware with cloud-based data services, the company provides comprehensive diagnostic and therapeutic tools for global healthcare providers, focusing on technical innovation and high-precision medical instrumentation.

Recent filings

Filing Released Lang Actions
关于预计触发可转债转股价格向下修正条件的提示性公告
Capital/Financing Update Classification · 82% confidence The document is a disclosure by the issuer concerning its outstanding convertible bonds (代码123065 “宝莱转债”) and a potential downward adjustment of the bond’s conversion price under the terms of the bond indenture. It is not an earnings report, ESG report, management change, nor an AGM notice. Instead, it is a specific update on a capital-market instrument (convertible bond) and related financing terms. This fits the definition of a Capital/Financing Update (CAP).
2026-05-26 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is a formal announcement of the 2025 Annual General Meeting (股东会) resolutions and detailed voting results on each proposal, including attendance, vote counts, and approvals. It does not present financial statements or the full annual report itself, nor is it a proxy statement or management discussion. It specifically reports shareholder vote results, fitting the definition of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2026-05-15 Chinese
广东精诚粤衡律师事务所关于广东宝莱特医用科技股份有限公司2025年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is a law firm’s legal opinion letter on the company’s 2025 annual shareholders meeting, containing detailed vote counts for each resolution (shareholder vote results). It is not an Annual Report nor an announcement of a report publication, but an official declaration of the voting outcomes at an AGM. This matches the "Declaration of Voting Results & Voting Rights Announcements" category (Code: DVA).
2026-05-15 Chinese
关于不向下修正宝莱转债转股价格的公告
Capital/Financing Update Classification · 75% confidence The document is an official company announcement describing the board’s decision on whether to adjust the conversion price of its convertible bonds (“宝莱转债”). It details the bond’s issuance, prior conversion price adjustments and the board resolution not to downward adjust the conversion price at this time. This is clearly a update on the company’s financing instruments and capital structure (convertible bond), so it falls under “Capital/Financing Update” (CAP).
2026-05-11 Chinese
第九届董事会第九次会议决议公告
Regulatory Filings Classification · 75% confidence The document is a board of directors meeting resolution announcement (第九届董事会第九次会议决议公告) concerning whether to adjust the conversion price of an outstanding convertible bond. It does not announce any changes in board or senior management (so not MANG), nor is it a shareholder meeting result (DVA). It is not a financial report itself, just a regulatory disclosure of a board resolution. Therefore it falls under the fallback category Regulatory Filings (RNS).
2026-05-11 Chinese
关于2026年度日常关联交易预计的公告
Regulatory Filings Classification · 85% confidence The document is a public announcement (“公告”) by Guangdong BOLIOTE Medical Technology Co., Ltd. regarding the estimated 2026 annual related-party transactions (“日常关联交易预计的公告”). It provides details of transactions with affiliates, governance approvals, pricing principles, and board/independent director opinions. It is not a financial report itself (e.g., annual or interim report), not an earnings release, not a call transcript, not a dividend notice, nor any of the other specific categories. It falls under miscellaneous regulatory disclosures. Therefore, it should be classified as a general Regulatory Filing (RNS).
2026-04-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.